RenovoRx a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, announced that on January 3 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma, bile duct cancer, by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. This is RenovoRx’s eighth US patent. "Our newest patent builds upon our strong IP portfolio, which now consists of eight US method and device patents, one EU delivery system patent, and eight additional pending patents in the US, EU, and Asia," said Shaun Bagai, CEO of RenovoRx. "Additionally, this additional patent bolsters the seven years of post-approval market exclusivity that we currently have with our lead oncology product candidate, RenovoGem(TM), through the Orphan Drug designation granted by the FDA for our first two indications."
Published first on TheFly
